CISATRACURIUM BESYLATE INJECTION SOLUTION

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Bahan aktif:

CISATRACURIUM (CISATRACURIUM BESYLATE)

Boleh didapati daripada:

PFIZER CANADA ULC

Kod ATC:

M03AC11

INN (Nama Antarabangsa):

CISATRACURIUM

Dos:

2MG

Borang farmaseutikal:

SOLUTION

Komposisi:

CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG

Laluan pentadbiran:

INTRAVENOUS

Unit dalam pakej:

10ML

Jenis preskripsi:

Prescription

Kawasan terapeutik:

NEUROMUSCULAR BLOCKING AGENTS

Ringkasan produk:

Active ingredient group (AIG) number: 0133260001; AHFS:

Status kebenaran:

CANCELLED POST MARKET

Tarikh kebenaran:

2019-03-28

Ciri produk

PRODUCT MONOGRAPH
PR
CISATRACURIUM BESYLATE INJECTION
Solution for Injection
20 mg/10 mL (2 mg/mL)
Cisatracurium
Non-depolarizing Skeletal Neuromuscular Blocking Agent
THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED
PROFESSIONALS FAMILIAR WITH ITS
ACTIONS, CHARACTERISTICS, AND HAZARDS.
Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Submission Control No.: 210419
Date of Revision:
November 07, 2017
_Product Monograph -_
_Pr_
_Cisatracurium besylate Injection_
_Page 2 of 32_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................9
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND
ADMINISTRATION..............................................................................12
OVERDOSAGE
................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
............................................................17
STORAGE AND
STABILITY..........................................................................................24
SPECIAL HANDLING INSTRUCTIONS
.......................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
............................................................................